All In Biotech

Drug Trial Radar · NCT02952508

Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom

An Open-Label, Multicenter, Phase 2 Study of Iopofosine I 131 (CLR 131) in Patients With Relapsed or Refractory (R/R) Select B-Cell Malignancies (CLOVER-1) and Expansion Cohort in Patients With Waldenstrom Macroglobulinemia (CLOVER-WaM)

Last checked: Nov 19, 2026Latest source record: Mar 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Jul 26, 2017

Primary completion

Jun 22, 2026

Study completion Dec 22, 2027

Sponsor

Lead sponsor
Cellectar Biosciences, Inc.Industry
Sponsor type
Industry
First posted
Nov 2, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Part A of this study evaluates iopofosine I 131 (CLR 131) in patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and central nervous system lymphoma (CNSL) who have been previously treated with standard therapy for their underlying malignancy. Part B (CLOVER-WaM) is a pivotal efficacy study evaluating IV administration of iopofosine I 131 in patients with WM that have received at least two prior lines of therapy.

Conditions

  • Waldenstrom Macroglobulinemia
  • Multiple Myeloma
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Lymphoplasmacytic Lymphoma
  • Marginal Zone Lymphoma
  • Mantle Cell Lymphoma
  • Diffuse Large B Cell Lymphoma
  • Central Nervous System Lymphoma

Interventions

  • Iopofosine I 131 single doseDrug

    Radiopharmaceutical

  • Iopofosine I 131 multiple doseDrug

    Radiopharmaceutical

  • Iopofosine I 131 fractionated doseDrug

    Radiopharmaceutical

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A [CLOVER-1] Clinical benefit rateTime frame: 84 days
  2. Part B [CLOVER-WaM] Major Response RateTime frame: 12 months

Locations

52 sites in 11 countries. Site status is shown where the registry gives one.

  • Cellectar Biosciences site

    Los Angeles, California

  • Cellectar Biosciences site

    Redlands, California

  • Cellectar Biosciences site

    Washington D.C., District of Columbia

  • Cellectar Biosciences site

    Jacksonville, Florida

  • Cellectar Biosciences site

    Miami, Florida

  • Cellectar Biosciences site

    Tampa, Florida

  • Cellectar Biosciences

    Atlanta, Georgia

  • Cellectar Biosciences site

    Maywood, Illinois

  • Cellectar Biosciences site

    Warrenville, Illinois

  • Cellectar Biosciences site

    Westwood, Kansas

  • Cellectar Biosciences site

    New Orleans, Louisiana

  • Cellectar Biosciences site

    Baltimore, Maryland

  • Cellectar Biosciences

    Bethesda, Maryland

  • Cellectar Biosciences site

    Boston, Massachusetts

  • Cellectar Biosciences

    North Bergen, New Jersey

  • Cellectar Biosciences site

    Buffalo, New York

  • Cellectar Biosciences site

    New York, New York

  • Cellectar Biosciences site

    Rochester, New York

  • Cellectar Biosciences site

    Durham, North Carolina

  • Cellectar Biosciences

    Canton, Ohio

  • Cellectar Biosciences site

    Cincinnati, Ohio

  • Cellectar Biosciences Site

    Charleston, South Carolina

  • Cellectar Biosciences

    Greenville, South Carolina

  • Cellectar Biosciences site

    Knoxville, Tennessee

  • Cellectar Biosciences site

    Dallas, Texas

  • Cellectar Biosciences site

    Dallas, Texas

  • Cellectar Biosciences site

    Houston, Texas

  • Cellectar Biosciences site

    Seattle, Washington

  • Cellectar Biosciences site

    Madison, Wisconsin

  • Cellectar Biosciences site

    Concord, New South Wales, Australia

  • Cellectar Biosciences

    Adelaide, South Australia, Australia

  • Cellectar Biosciences

    Salvador, Estado de Bahia, Brazil

  • Cellectar Biosciences

    Curitiba, Paraná, Brazil

  • Cellectar Biosciences

    Porto Alegre, RioGrande Do Sul, Brazil

  • Cellectar Biosciences

    Blumenau, Santa Catarina, Brazil

  • Cellectar Biosciences Site

    Hradec Králové, Czechia

  • Cellectar Biosciences

    Helsinki, Finland

  • Cellectar Biosciences

    Pessac, France

  • Cellectar Biosciences

    Poitiers, France

  • Cellectar Biosciences site

    Athens, Greece

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.